<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Selux-Diagnostics on Bioecon</title><link>https://en.bioecon.ru/companies/selux-diagnostics/</link><description>Recent content in Selux-Diagnostics on Bioecon</description><generator>Hugo</generator><language>en-US</language><lastBuildDate>Mon, 20 Jul 2026 17:06:23 +0700</lastBuildDate><atom:link href="https://en.bioecon.ru/companies/selux-diagnostics/index.xml" rel="self" type="application/rss+xml"/><item><title>Rapid antibiotic-resistance tests</title><link>https://en.bioecon.ru/technology/rapid-antibiotic-resistance-tests/</link><pubDate>Mon, 20 Jul 2026 00:00:00 +0000</pubDate><guid>https://en.bioecon.ru/technology/rapid-antibiotic-resistance-tests/</guid><description>Platforms that determine which antibiotics a specific infecting pathogen is susceptible or resistant to in hours instead of the 2-3 days conventional culture-based susceptibility testing requires, guiding targeted rather than empiric antibiotic therapy: Accelerate Diagnostics and T2 Biosystems and Selux Diagnostics in the US, Q-linea in Sweden, and Autobio Diagnostics in China.</description></item></channel></rss>